These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36647946)

  • 21. Oral versus intravenous fluoropyrimidines for colorectal cancer.
    Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence.
    Laukhtina E; Abufaraj M; Al-Ani A; Ali MR; Mori K; Moschini M; Quhal F; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NC; Fajkovic H; Soria F; Enikeev D; Shariat SF;
    Eur Urol Focus; 2022 Mar; 8(2):447-456. PubMed ID: 33762203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
    Vartolomei MD; Porav-Hodade D; Ferro M; Mathieu R; Abufaraj M; Foerster B; Kimura S; Shariat SF
    Urol Oncol; 2018 Sep; 36(9):389-399. PubMed ID: 29884342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
    Sylvester RJ; Oosterlinck W; Holmang S; Sydes MR; Birtle A; Gudjonsson S; De Nunzio C; Okamura K; Kaasinen E; Solsona E; Ali-El-Dein B; Tatar CA; Inman BA; N'Dow J; Oddens JR; Babjuk M
    Eur Urol; 2016 Feb; 69(2):231-44. PubMed ID: 26091833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Abern MR; Owusu RA; Anderson MR; Rampersaud EN; Inman BA
    J Natl Compr Canc Netw; 2013 Apr; 11(4):477-84. PubMed ID: 23584348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
    Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
    Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Shen P; Yang J; Wei W; Li Y; Li D; Zeng H; Wang J
    BJU Int; 2012 Sep; 110(6 Pt B):E209-15. PubMed ID: 22288379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
    Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
    Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Galesloot TE; Grotenhuis AJ; Kolev D; Aben KK; Bryan RT; Catto JWF; Cheng KK; Conroy S; Dyrskjøt L; Fleshner NE; James ND; Lamy P; Lindskrog SV; Malats N; Mengual L; Verhaegh G; Zeegers MP; Kiemeney LALM; Vermeulen SH
    Eur Urol Oncol; 2022 Feb; 5(1):70-83. PubMed ID: 34353775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis.
    Daryanto B; Purnomo AF; Seputra KP; Budaya TN
    Med Arch; 2022 Jun; 76(3):198-201. PubMed ID: 36200115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of intravenous chemotherapy after TURBT for high-risk nonmuscle invasive bladder cancer: results of a retrospective study.
    Chen J; Zhang Z; Nie Z; Qiu J
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):13905-13913. PubMed ID: 37540255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
    Vartolomei MD; Ferro M; Cantiello F; Lucarelli G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdona S; Verze P; La Rocca R; Borghesi M; Schiavina R; Brunocilla E; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Serretta V; Russo GI; Morgia G; Terracciano D; Musi G; de Cobelli O; Mirone V; Shariat SF
    Clin Genitourin Cancer; 2018 Dec; 16(6):445-452. PubMed ID: 30077463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials.
    Quan Y; Jeong CW; Kwak C; Kim HH; Kim HS; Ku JH
    Medicine (Baltimore); 2017 Oct; 96(42):e8300. PubMed ID: 29049231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: A systematic review and meta-analysis.
    Li S; Zeng XT; Ruan XL; Wang XH; Guo Y; Yang ZH
    Exp Ther Med; 2012 Oct; 4(4):685-692. PubMed ID: 23170127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.